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The management of Hepatitis
C infection (HCV) was the sub-
ject of an expert "consensus
panel" discussion at the
National Institutes of Health
this past June. From the dis-
cussions at the meeting,
guidelines for testing, treating
and preventing HCV were
developed and are now  post-
ed on the internet (www.con-
sensus.nih.gov). HCV preven-
tion in prison is also the sub-
ject of a special issue of
the Morbidity and Mortality
Weekly Report, to be published later this year. Events at the consensus meeting and aspects of the
two publications that concern correctional health providers are reviewed in this HEPP Report. 
HCV IN JAILS AND PRISONS UNDERESTIMATED
HCV is the most common chronic blood borne infection in the United States.1 The number of infect-
ed individuals is reaching "epidemic proportions," according to W. Ray Kim, M.D, of the Mayo Clinic,
one of the experts invited to speak at the NIH Consensus conference.2 Most of these infections are
not new, and were acquired in previous years or decades due to transfusions, injection drug use or
other high-risk behaviors. About 4 million Americans, or 1.8% of the US population, are estimated to
have antibody to HCV, indicating ongoing or previous infection with the virus. At the NIH conference,
Dr. Kim suggested that these data, based on NHANES3 surveys that excluded individuals from high-
er risk groups (drug addicts and prisoners), might underestimate the prevalence of HCV in the US
population.2
The most significant threat HCV poses is chronic liver disease.  Chronic liver disease, (if defined as
consistently abnormal ALT values with a positive test for HCV) develops in at least 75% of those
infected (see Figure 1). Liver failure from chronic HCV is the most common reasons for liver trans-
plants in the United States.3
The prevalence of HCV infection among US prisoners is at least ten-fold higher than that in the gen-
eral population.4 For women prisoners, who are often incarcerated for crimes related to sex and/or
drugs, the rate of HCV is even higher than in men.
Hispanics and non-Hispanic blacks have higher
rates of HCV and HIV than do whites. The over-
representation of persons of color in jails and pris-
ons also contributes to the increased rate of HCV
and HIV among inmates (see Figure 2). Among
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Recommendations for those on the Frontline
Against Hepatitis C
NOTE: NIH Consensus Statements are prepared by a non-advocate, non-Federal panel of experts,
based on (1) presentations by investigators working in areas relevant to the consensus questions dur-
ing a 2-day public session; (2) questions and statements from conference attendees during open dis-
cussion periods that are part of the public session; and (3) closed deliberations by the panel during the
remainder of the second day and morning of the third. The resulting statement is an independent report
of the panel and is not a policy statement of the NIH or the Federal Government. The statement reflects
the panel's assessment of medical knowledge available at the time the statement was written.
Consensus statements are often updated as medical knowledge advances.
Jules Levin*, Joseph Bick*, M.D., and Elizabeth Stubblefield*
Figure 1: Number of people with the given condition out
of an original population of 275 exposed to hepatitis C (HCV).6
1 (= 3% of 33, 0.45% of 220, 0.36% of 275)
35 (= 15% of 220, 12% of 275)
220 (= 80% of 275)
275 (= sample of those 
exposed to HCV)
HCC*
CIRRHOSIS
CHRONIC 
HCV INFECTION
EXPOSED TO HCV
*HCC= Hepatocellular Carcinoma
many HIV-infected cohorts, 30% have
HCV, while among those infected with HIV
by injection drug use, 60-90% are estimat-
ed to have HCV.5
As with many other blood-borne diseases,
the true prevalence of HCV is difficult to
estimate.  HCV is usually asymptomatic for
years, and often people are unaware of
their infection or do not seek care.
Furthermore, until 1999, death certificates
did not have a separate code for HCV-relat-
ed deaths. However, the number of people
known to be infected with HCV is increas-
ing. Among HIV-infected individuals, chron-
ic liver disease is now the most common
cause of death. Currently, it is estimated
that the US spends $1.6 billion on HCV
hospitalizations per year. According to Dr.
Kim, as more and more infections are diag-
nosed, these expenditures are likely to
increase exponentially.2
WHAT CAN CORRECTIONAL
HEALTH CARE PROVIDERS
DO?
Identify
The epidemiology of HCV makes correc-
tional institutions pivotal sites for US efforts
to identify those who are infected with HCV.
News from this year's Conference on
Retroviruses and Opportunistic Infections
(CROI) highlights the fact that most of
those infected with HIV are unaware of
their disease.8 Unfortunately, according to
the experts at the NIH consensus panel,
this is also true of HCV. Thus a simple but
powerful first step is to provide ready
access to HIV and HCV testing. All prison-
ers should be evaluated for HCV risk fac-
tors. Those with HCV risks and any other
prisoner who requests testing should be
offered it.  
HCV is most readily diagnosed by the
detection of antibody in serum. According
to Jean-Michel Pawlotsky, M.D., one of the
experts on the NIH consensus panel, cur-
rent FDA-approved antibody tests for HCV
are highly sensitive and specific (99%),
reproducible, and inexpensive, which
makes them suitable for use in screening
at-risk populations. (Contrary to what was
said at the NIH Conference, the CDC still
recommends a confirmatory test, and for
screening purposes, i.e., not medical man-
agement purposes, a RIBA is recommend-
ed).  A negative HCV antibody (EIA) test is
sufficient to exclude a diagnosis of chronic
HCV infection in most immune-competent
patients. Rarely, those who are on
hemodialysis or who are otherwise
immune-deficient may have a false nega-
tive EIA. Conversely, false positive results
can be obtained in those with autoimmune
disorders. In these individuals, assays for
HCV RNA are useful adjuncts.9
Educate
Once individuals know their HCV status,
education about HCV enables them to
understand their illness, better care for
themselves, and prevent transmission to
others. Patients should be advised that
continued alcohol use by those with HCV
infection can hasten the progression of liver
disease. Providers should also discuss
drug and alcohol addiction treatment and
anti-HCV treatment options. Inmate-led
peer education programs can be invaluable
in fostering better understanding of HCV
and HIV. HCV- infected patients who are
not already immune should be vaccinated
against hepatitis A and, if indicated
because of other risk factors, hepatitis B.10 
Prevent further transmission
The use of a harm reduction model helps
patients prevent further transmission of
HCV. The risk for transmission of blood
borne pathogens is dramatically increased
among IDUs who are not utilizing harm
reduction techniques, making drug treat-
ment and the availability of clean needles
key components of prevention.1
Evaluate for treatment: Who are the best
candidates?
Those patients who are the best candi-
dates for treatment are those with chronic
HCV who lack significant contraindications
(see Table 1) and are at the greatest risk for
progression to cirrhosis (measurable HCV
RNA, a liver biopsy with portal or bridging
fibrosis and at least moderate inflammation
and necrosis, and elevated ALT values).
More data has accumulated demonstrating
that those with HIV infection can be effec-
tively treated for HCV. As a result, the NIH
consensus panel recommended that HIV-
infected people be considered for HCV
treatment. 
The 2002 panel also reversed the 1997
recommendations that excluded treatment
for all active substance abusers. As report-
ed at the meeting, recent experience has
demonstrated the feasibility and effective-
ness of treating HCV in some people who
use injection drugs.12 Since IDUs comprise
one of the largest groups of HCV patients,
successful treatment may lead to reduced
transmission. Linking IDUs to drug-treat-
ment programs enhances the management
of HCV-infected IDUs. In some settings,
HCV therapy has been successful even
when the patients have not been complete-
ly abstinent from continued drug use or are
on daily methadone.13
Patients with mild mental health problems
may also be eligible for treatment, but
should be closely monitored throughout the
process as interferon (IFN) can exacerbate
depression.13
Measure Viral Load
VL measurements can be used to confirm
active infection, assess response to thera-
py, and evaluate end of treatment and sus-
ained responses. Unlike HIV infection,
HCV Viral load does not correlate with the
severity of HCV infection. Viral load does
correlate with the likelihood of a response
to antiviral therapy. Rates of response to a
course of IFN and ribavirin (RBV) are high-
er in patients with low levels of HCV RNA
(usually defined as below 2 million copies
per milliliter). 
Monitor
Monitoring HCV RNA levels during the
early phases of treatment may provide
information on the likelihood of a response.
A viral load reduction of 2 log or more at
week 12 indicates a positive response to
therapy, and treatment should be continued
(see HEPPigram, page 6). If viral load has
not been reduced by 2 log (90%) or more at
2
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Figure 2: Percentage of inmates with HCV infection (HEPP Study, 2002)7
States participating in a HEPP phone survey earlier this year reported the following estimates of
HCV prevalence. The data for each state is collected using different measures. (S*= Suppressed)
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Dear Colleagues:
As the summer comes to a close, we would like to highlight a few changes at HEPP.  First,
we have changed the name of our publication to HEPP Report.  Our mission will continue
to be to provide you updates on the management of infectious disease in corrections, with
a particular focus on HIV and hepatitis.  Second, Dr. Joseph Bick has agreed to serve wit
Dr. Anne De Groot as co-chief editor of the HEPP Report.  Dr. Bick's decade of experience
as a correctional infectious disease consultant will serve him well in his new role.  Lastly, we
are pleased to announce that Dr. Peter Piliero of the New York State Department of
Corrections has joined us as an associate editor.
This month, we discuss the updated NIH guidelines for hepatitis C.  HEPP Report members
Anne De Groot, Joe Paris, Lou Tripoli and Lester Wright attended this important meeting,
held in June in Washington DC.  Jules Levin, founder and director of the National AIDS
Treatment Advocacy Project (NATAP) who has an encyclopedic knowledge of the HIV/HCV
co-infection literature, co-wrote the main article this month.  Our advisors and editors par-
ticipated actively in the editorial process.  The article is written for and by correctional pro-
fessionals with applications of the guidelines to the correctional setting firmly in mind.  
It is important to note that the NIH panel did not address important issues such as "mainte-
nance therapy" for persons who fail to achieve cure, nor was the panel clear about the dura-
tion of treatment for HIV/HCV co-infected persons who have genotype 2 or 3.  Future
updates of the guidelines may be clearer on this point.
After reviewing this issue, readers should be able to identify which patients are eligible for
HCV treatment, list the most effective diagnostic tools for HCV treatment, quantify the sever-
ity of the HCV epidemic in prisons and jails, and suggest which patients are more likely to
respond to HCV therapy.
Thank you for your continued support for HEPP!
Sincerely,
Anne De Groot, M.D.
Letter from the Editor
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4week 12, there is a low likelihood that a
patient will achieve a sustained viral
response, and discontinuation of therapy
may be considered.14 Some patients, partic-
ularly those with HIV, may take longer to
achieve a 2 log response. Furthermore, if a
patient has advanced HCV, continuing ther-
apy may be useful despite less than a 2 log
reduction because a course of treatment
that does not result in eradication of HCV
may slow HCV disease progression.15
GENOTYPE
There are six known HCV genotypes.
Patients with genotype 2 or 3 are two to
three times more likely to achieve a sus-
tained viral response to treatment than those
with genotype 1. The duration of combina-
tion therapy with pegylated IFN who are not
co-infected and do not have genotype 1 is
usually 24 weeks, while co-infected patients
and those with genotype 1 are usually treat-
ed for at least 48 weeks (See HEPPigram,
page 6). 
THE ROLE OF LIVER BIOPSY
The NIH consensus panel emphasized the
role of liver biopsy in the management of
HCV. Biopsies grade the severity of disease
and stage the degree of fibrosis and perma-
nent architectural damage in a patient.
Radiological testing such as ultrasound can-
not indicate the stage of disease except in
the setting of advanced cirrhosis. Measuring
ALT also does not reliably assess the stage
of liver disease, particularly in HIV-infected
patients. While the majority of HCV patients
with consistently normal ALT have early
HCV disease, 22% may have more
advanced disease.16 Because patients with
genotypes 2 and 3 respond so well to treat-
ment,  there was some debate about the
need for biopsy prior to treatment in those
patients (See HEPPigram, page 6). In addi-
tion, among HIV-infected patients, a higher
percentage of patients with normal ALT may
have moderate or more severe liver disease.
Therefore, some experts suggest that
patients with consistently normal ALT be
treated no differently than patients with con-
sistently abnormal ALTs.16
In addition to more accurate staging of dis-
ease, biopsies also confirm the HCV diagno-
sis, exclude alternative diagnoses, predict
responsiveness to treatment, and provide a
baseline for future comparison.17 The biopsy
can provide extremely useful information,
but lack of access to liver biopsy should not
exclude appropriately selected patients from
having access to HCV treatment.
TREATMENT OF HEPATITIS C
The therapy of chronic hepatitis C has
evolved steadily since alpha IFN was first
approved for use in this disease more than
10 years ago. At the present time, the opti-
mal regimen for most patients appears to be
a 24- or 48-week course of the combination
of pegylated IFN and RBV.
The development of pegylated IFN (peg
IFN) and the use of peg IFN in combination
with RBV (combination therapy) are impor-
tant advancements in the treatment of HCV
that were emphasized during the NIH con-
ference (see HEPP News, April 2002). Two
forms of peg IFN have been developed and
studied in large clinical trials: peg IFN  alfa-
2a (Pegasys: Hoffman La Roche, Nutley,
NJ) and peg IFN alfa-2b (Pegintron:
Schering-Plough Corp., Kenilworth, NJ).
CURABLE?
Combination therapy leads to rapid improve-
ments in serum ALT levels and disappear-
ance of detectable HCV RNA (end of treat-
ment response) in up to 70% of monoinfect-
ed patients.  For patients with genotype 2 or
3, response rates in studies are 75-90%. For
patients with genotype 1, response rates are
30-46%. Preliminary data from ongoing
studies suggest that HIV-coinfected patients
will have lower response rates. Success
depends on several factors including geno-
type, viral load, and stage of disease. For
patients who maintain negative HCV RNA
for 24 weeks after stopping HCV therapy,
results from several studies show 98%
remain HCV RNA negative (sustained
response). Small studies following patients
for up to 11 years show well over 90% of
those who achieve a sustained response
remain HCV RNA negative. In some patients
who were HCV RNA negative, HCV could no
longer be found in the liver. Unlike the situa-
tion with HIV, the HCV virus cannot integrate
into the host genome, and therefore eradica-
tion of the virus is possible. At the NIH con-
sensus panel, Dr. Jay H. Hoofnagle pro-
nounced HCV "curable".18 Indeed, since the
last consensus panel on HCV convened in
1997, the availability of highly effective com-
bination therapy that can eradicate HCV
infection has lead many experts to consider
treatment where previously they might not
have treated. In order to evaluate the clinical
outcomes and survival, however, studies of
long-term follow-up for these patients and
coinfected patients is necessary. 
SPECIAL CONSIDERATIONS
FOR HIV/HCV CO-INFECTION
All HIV-infected persons should be screened
for HCV. The 2002 NIH consensus panelists
recommended that studies are needed to
determine the best strategies for treating
HCV and HIV co-infected patients. Co-
infected patients may have an accelerated
course of HCV disease. As a result, some
clinicians believe that early treatment of
HCV is indicated in those who are HIV
infected. Thus far, studies of co-infected
individuals have enrolled mainly patients
with "stable" (usually defined as CD4 counts
>300 and HIV viral loads <5000) HIV infec-
tion and well-compensated liver disease.
Preliminary studies suggest that combina-
ion (IFN/RBV) therapy is more efficacious
than IFN monotherapy in those who are co-
infected.19
Small studies done several years ago
reported that HCV and HIV-co-infected
patients responded to therapy just as well as
mono-infected patients.20 More recently, bet-
ter designed studies suggest the response
rate in co-infected patients is likely to be
lower than in those who are not HIV-infect-
Recommendations...
(continued from page 2)
Continued on page 5
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1997 NIH Consensus Statement
2002 NIH Consensus Statement
Figure 3: The Change in Balance: Treatment of HCV in an HIV-Coinfected Patient
A reversal from the recommendations in 1997, in 2002, the benefits of HCV treatment in 
HIV-coinfected patients appear to outweigh the drawbacks.
Drawbacks of treatment
Drawbacks of treatment
Benefits of treatment
Benefits of treatment
–Ongoing substance abuse
–Severe depression or other  
psychiatric disorders
–Decompensated cirrhosis
–Autoimmune disease
–Older age
–Pregnancy
–Renal failure
Table 1: Patients with the following
conditions may face risks that outweigh
the benefits of therapy:11
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ed. This reduced response may be attrib-
uted to the impairment HIV causes to the
immune system and/or higher therapy dis-
continuation rates due to drug side effects
and toxicities. Although it has not yet been
well researched, patients co-infected with
HIV may require 48 weeks therapy or
longer regardless of whether they have
genotype 1 or 2. Speaking at the NIH
Consensus Conference, Dr. David Thomas
of Hopkins suggested that the "balance has
shifted" in favor of treatment of HIV-infected
patients, even though larger studies will be
needed to determine the rate of progression
of HCV in these patients, the duration of
therapy that may be required and their over-
all response to treatment (See Figure 3).
When asked by a Consensus Conference
audience member what CD4 cutoff should
be used to exclude patients from treatment,
Dr. Thomas could not define one. He went
on to say that good control of HIV infection
was essential if HCV were to be treated, but
otherwise he could see no contraindication
to treatment of HIV-infected patients.21
An additional concern is that co-infected
patients may experience more side effects
and adverse events, such as anemia and
leukopenia. These side effects can make
adherence to therapy more challenging.
A high percentage of co-infected patients
are African-Americans and greater than 90%
have genotype 1. Patients with genotype 1
have a lower rate of response to therapy.
One study showed that African-Americans
with genotype 1 experienced lower
response rates than Caucasians with geno-
type 1, suggesting that factors other than
genotype may also be responsible.23 These
factors have not been well defined, and
merit further research.
Side effects
Side effects of therapy can include fatigue,
irritability, emotional distress, weight loss,
nd depression. Adverse laboratory events
can include anemia, leukopenia, and throm-
bocytopenia. More uncommonly, therapy
can cause autoimmune disease (particularly
thyroid disease), and suicidal ideation or
attempts. For these reasons, close follow-up
of patients on therapy is essential. Ideally,
patients should be seen weekly for the first
four weeks after initiation of therapy. After
the first month, patients who are doing well
can be seen less often i.e. every four weeks.
It is important for prisoners to be able to
inform the clinician of all side effects they
experience so that effective interventions
can be initiated. Support services are need-
ed to guide patients through the process of
starting and maintaining therapy.
OUTCOMES OF THERAPY
For those without cirrhosis, achieving a sus-
tained response to therapy should prevent
progression to decompensated liver disease
or cancer. Experts believe that a sustained
response to therapy among people with cir-
rhosis should also prevent progression, but
studies are still inconclusive.15 Several stud-
ies previously conducted provide evidence
that IFN use in patients with cirrhosis and
non-responders can slow or reverse disease
progression.24 These results indicate that
patients with cirrhosis who achieve a sus-
tained viral response have a good chance of
stopping and perhaps reversing disease
progression. Further study, however, is nec-
essary. 
CONCLUSION
At the NIH conference two significant state-
ments were made: that HCV is now an epi-
demic in the US, and it is curable in many
cases. The consensus panel also expanded
its recommendations to treat HCV in popula-
tions that had previously not been consid-
ered eligible (HIV-infected patients and for-
mer or active drug addicts). Dosing sched-
ules for the drugs described in the consen-
sus statement are available in the March
2002 issue of HEPP News (www.hivcorrec-
tions.org). The panel also reinforced the
need to identify infected patients, educate
them about their disease, and initiate treat-
ment in those most likely to respond. Studies
are currently underway to better understand
the impact and treatment of HIV and HCV
co-infection. Clinicians working in correction-
al settings will continue to be on the front line
of this epidemic for the foreseeable future.
Recommendations...
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6HEPPigram: One Approach To HCV Treatment
Obtain genotype and HCV viral loadb
Genotype 1, 4, 5 or 6
Obtain Liver Biopsy Initiate therapy with pegylated 
interferon + ribavirin for 24 weeksd, e
END OF TREATMENT FOLLOW-UP
Obtain HCV RNA load at end of treatment
Genotype 2 or 3c
"Good prognosis" 
without  immediate 
treatment
"Poor prognosis" 
without treatment
Negative
Repeat viral load
24 weeks after end
of treatment
Not Cured
Negative
Cured Consult an HCV expert
Positive
Positive
Initiate therapy with
pegylated interferon
and ribavirin.Check VL
at 12-24 weeksd, e
VL decrease is >2 log VL decrease is <2 log
Defer
Treatment
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Continue treatment for
total of 48 weeks
Some experts would
discontinue, while oth-
ers would continue
treatment for a total of
48 weeks. Cure much
less likely (<5%).
Proceed to End of Treatment Follow-up
(at right)
a- Pt has consistently abnormal ALT with positive HCV PCR (see main article, GENOTYPE, Page 4).
b- Some experts suggest a liver biopsy for all cases.
c- Biopsy can be considered at this point, but NIH guidelines may be silent.
d- See NIH Treatment Guidelines for specific treatment recommendations.
e- Current practice is not the same as FDA labeling.
This flow chart is for patients with chronic HCV infection who are eligible for treatment. At present, the only difference for HIV and HCV
co-infected patients with genotype 2 or 3 is that the duration of treatment is unclear. See Editor’s Letter, page 3.
6th Annual United States
Conference on AIDS (USCA)
September 19-22, 2002
Anaheim, California
Visit: www.nmac.org/usca2002/
Call: Paul Woods, 
202.483.6622 ext. 343
Email: pwoods@nmac.org
Management of HIV/AIDS 
in the Correctional Setting:
"Occupational Exposure
to Viruses"
Satellite Videoconference
October 15, 2002;
12:30-3:30 EST
CME & Nursing Credits Available
Visit: www.amc.edu/Patient/HIV/
hivconf.htm
Call: 518.262.4674
E-mail: ybarraj@mail.amc.edu
26th National Conference on
Correctional Health Care
October 19-23, 2002
Nashville, Tennessee
Fee: before Sept. 6- 
$225 members
$300 non-members
after Sept.6- 
$275 members
$350 non-members
Visit: http://www.ncchc.org
Call: 773.880.1460
Email: ncchc@ncchc.org
North American AIDS
Treatment Action Forum
December 8-11, 2002
New Orleans, Louisiana
Fee: before Nov. 8- 
$150 members
$175 non-members
after Nov.8- $225
Call: Paul Woods, 
202.483.6622 ext. 343
Email: pwoods@nmac.org
Visit: www.nmac.org/nataf/2002/
Save the 
Dates
7
CDC Data Shows High Incarceration Rate
Among U.S. HIV/AIDS Population
At the XIV International AIDS Conference in
Barcelona, Spain this summer, the CDC pre-
sented data from their investigation of how many
people with HIV/AIDS in the United States have
ever been incarcerated. Of the 2,639 patients
questioned, 48% answered that they had been
incarcerated at least once. Twelve percent of
that group were initially diagnosed in a correc-
tional facility. Nakashima AK, Campsmith ML et
al. XIV IAC, Barcelona Spain, 2002. Abstract
WePeC6127.
Updated Report on Health of Inmates Now
Available
An updated Health Status of Soon-to-be-
Released Inmates has just become available
from the US Department of Justice Statistics.
Compiled by experts in communicable diseases,
chronic diseases, and mental health, the report
assesses the health status of the 11.5 million
Americans who cycle through correctional sys-
tems each year. Eighteen percent of people in
the US with HCV cycle through corrections every
year, along with 8% of those with HIV and 33%
of those with active tuberculosis. Highlights were
shared at the International AIDS Conference.
The report available at www.ojp.usdoj.gov or
www.ncchc.org/pubs_stbr.html
Price Freeze on AIDS Drugs
Abbott Laboratories, Pfizer, GlaxoSmithKline,
Hoffmann-LaRoche, and Bristol-Myers Squibb
have announced price freezes on their antiretro-
viral medications for as long as two years.  Many
of the price freezes apply to wholesale prices
and/or costs to state ADAP programs. New York
Times, 6/21/02
Number of Known Boston HCV Cases Triples
in Four Years
A recent report from the Public Health
Commission found that the number of hepatitis C
cases in Boston rose 300% from 1998 to 2001.
Experts believe this increase reflects public
health campaigns that have encouraged people
to get tested, not a new outbreak of the virus.
HCV has a long incubation period, meaning that
p ople recently tested and diagnosed may have
been infected for many years previously. Boston
Globe, 6/5/02
Adefovir: Useful Against Hepatitis B/HIV
Coinfection
A new drug that reduces serum levels of hepati-
tis B virus (HBV) is likely to be FDA-approved by
the end of the year.  Gilead's "Adefovir Dipivoxil"
has shown activity against wild type and lamivu-
dine-resistant HBV in patients co-infected with
HIV. Adefovir allow easier administration; it can
be taken once a day, with or without food, does
not interact with hepatic cytochrome P450 and
has not shown any clinically significant interac-
tions with other drugs. Gilead offers an early
access program to all patients, including
inmates, who can provide informed consent. For
more information call 1-800-GILEAD-5, or visit
www.gilead.com. (Benhamou Y et al. The
Lancet, 358: 2001 Sept 1; Benhamou Y et al.
poster 40774, 52nd AASLD, 2001.)
Lamivudine is as Effective in HBV Treatment
in Children as in Adults
An international study of children with chronic
hepatitis B demonstrated that lamivudine creates
a higher virologic response than placebo after 52
weeks of treatment. The study compared 191
children randomly assigned to receive lamivu-
dine to 97 children who received placebo.  Jonas
et al. Clinical trial of lamivudine in children with
chronic hepatitis B. NEJM: 2002 May,
346(22):1706-1713.)
Inside News
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Resources & Websites
HCV
HCV Prison Support Project- For prisoners
who have just been released from prison and
need information on how to apply for their state’s
Medicaid, general information on hepatitis C and
how to proceed in getting care and treatment. 
1-866-HEPINFO (437-4636) 
NIH Hepatitis C Consensus Statement
http://consensus.nih.gov/
HIV
AmfAR HIV/AIDS Treatment Directory:
NEW 2002 Summer Edition
Free (incl. shipping); large quantities available for
clinic settings.
Contact Gretchen.Schmelz@amfar.org or 
call 212.806.1762
National AIDS Treatment and Advocacy
Project
www.natap.org
Department of Health and Human Services
www.dhhs.gov
XIV International AIDS Conference
http://www.aids2002.com
Corrections
New Bureau of Justice Statistics Report:
Prison and Jail Inmates at Midyear 2001
http://www.ojp.usdoj.gov/bjs/pub/pdf/pjim01.pdf
Correctional Health Care:Guidelines for the
Management of an Adequate Delivery System,
2001 Update
http://www.nicic.org/pubs/2001/017521.htm
Three Part Report: "Corrections, Inc."
This American Radio Works report explores 
various aspects of corrections, and can be heard
or read at http://www.americanradioworks.org/
features/corrections/index.html
NIH Hepatitis C
Consensus 
document is available at 
http://consensus.nih.gov/
cons/116/116cdc_intro.htm
Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through March 31, 2003. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1.  The most accurate gauge of the activity of a patient's liver 
disease is:
a) a liver biopsy 
b) quantitative HCV PCR
c) measuring ALT
d) measuring viral load
e) HCV antibody (EIA) test
2.  Which of the following HCV-infected individuals might be 
candidates for HCV treatment?
a) Patients with HIV infection
b) Active substance abusers
c) Patients with mild mental health problems
d) All of the above
e) None of the above
3.  What is the best predictor of the potential for HCV "cure"?
a) HCV viral load has decreased by more than 2 log after 
24 weeks of treatment.
b) HCV viral load has decreased by more than 2 log after 
48 weeks of treatment.
c) HCV viral is negative 24 weeks after the end of treatment.
d) HCV RNA is negative after 24 weeks of treatment.
e) None of the above; there is no cure for HCV.
4.  According to a recent CDC study, what proportion of
HIV/AIDS patients have ever been incarcerated?
a) 12%
b) 28%
c) 39%
d) 48%
e) 63%
5.  Approximately what proportion of those who become infected
with HCV will develop chronic liver disease?
a) 12-15%
b) 35-45%
c) 50%
d) 75-80%
e) 90-95%
6.  Patients with genotype 2 or 3 are two to three times more
likely to achieve a sustained viral response to treatment than
those with genotype 1.
a) True
b) False
BROWN MEDICAL SCHOOL •  OFFICE OF CONTINUING MEDICAL EDUCATION •  BOX G-A2  •  PROVIDENCE, RI 02912
The Brown Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME)to provide continuing medical 
education activities for physicians.  
The use of the Brown Medical School name implies review of the educational format and material only.  The opinions, recommendations 
and editorial positions expressed by those whose input is included in this bulletin are their own.  They do not represent or speak for the 
Brown Medical School.
For Continuing Medical Education credit please complete the following and mail or fax to 401.863.2660 or 
register online at www.hivcorrections.org. Be sure to print clearly so that we have the correct information for you.
Name __________________________________________________________________ Degree ____________________
Address ____________________________________________________________________________________________
____________________________________________________________________________________________________
City ____________________________________________________ State ________ Zip ________________________
Telephone ________________________________________________ Fax ______________________________________
HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1     
HEPPigram 5  4  3  2  1   5  4  3  2  1  
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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